基因组学和定量药理学用于化疗药物治疗肿瘤患者的个性化治疗研究进展  

Research progress of personalized treatment for cancer patients with chemotherapy drugs using genomics and quantitative pharmacology

作　　者：余金十 李茜 崔勇 YU Jinshi;LI Qian;CUI Yong(GCP Office,Shenzhen Qianhai Shekou Free Trade Zone Hospital,Shenzhen 518067,China)

机构地区：[1]深圳市前海蛇口自贸区医院药物临床试验机构办公室,广东深圳518067

出　　处：《中国海洋药物》2024年第6期73-82,共10页Chinese Journal of Marine Drugs

基　　金：深圳南山区卫生健康局卫生科技项目(NS2022080)资助。

摘　　要：癌症是威胁公众健康的主要疾病,严重危害人类的生命健康安全,是全球主要死因之一。目前,使用化疗药物是丧失手术根治机会中晚期癌症患者的优选,但其治疗效果和不良副作用给治疗带来了巨大的挑战,对患者的生活质量造成严重影响。因此,化疗药物的个性化治疗在提高治疗效果和减少副作用等方面都具有重要意义。其中,基因组学和定量药理学等研究的个性化治疗已经开始打破传统医学的边界,成为精准医学研究的重要方向。本文综述了包括奥沙利铂、海洋药物艾日布林和阿糖胞苷以及紫杉醇4种常见的化疗药物相关的基因组学和定量药理学的研究进展。Cancer is a major disease that threatens public health and seriously endangers human life and health security.It is one of the leading causes of death worldwide.Currently,the use of chemotherapy drugs is preferred for advanced cancer patients who have lost the opportunity for surgical cure.However,the treatment effects and adverse effects pose significant challenges to the treatment,severely impacting the quality of life for patients.Therefore,personalized treatment with chemotherapy drugs is important for improving treatment effectiveness and reducing side effects.Personalized treatments based on genomics and quantitative pharmacology have begun to break the boundaries of traditional medicine and have become an important direction in precision medicine research.This article reviews the research progress in genomics and quantitative pharmacology related to four common chemotherapy drugs:oxaliplatin,marine drug irinotecan,and capecitabine,as well as paclitaxel.

关 键 词：基因组学 定量药理学 奥沙利铂 阿糖胞苷 

分 类 号：R931.77[医药卫生—生药学]